SCHEMBL3366483

SCHEMBL3366483

[CH2]CCCCCC(C)CCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.52
OPRM1 P35372 1/20 0.44
LMNA P02545 2/20 0.42
SPHK1 Q9NYA1 1/20 0.41
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41
PRKCZ Q05513 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKD1 Q15139 1/20 0.41
DNM1 Q05193 2/20 0.40
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812974 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL199331 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201050 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201116 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL25178063 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL25186110 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL25181811 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL25185241 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL25185981 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL21219900 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592351-B2 Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds GRUENENTHAL GMBH (DE) 2009-09-22 US claimed
US-20070099896-A1 Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds GRUENENTHAL GMBH (DE) 2007-05-03 US claimed
EP-1756105-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS Grünenthal GmbH (DE) 2007-02-28 EP claimed
WO-2005105798-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS Grünenthal GmbH (DE) 2005-11-10 WO claimed
CN-118201905-A Cationic lipid 武田药品工业株式会社 2024-06-14 CN disclosed
WO-2023085299-A1 CATIONIC LIPID 武田薬品工業株式会社 2023-05-19 WO disclosed
CN-106893581-B Organic electroluminescent compounds, organic electroluminescence device and its application 南京高光半导体材料有限公司 2019-11-05 CN disclosed
CN-106892915-B Organic compound, organic electroluminescence device and its application 南京高光半导体材料有限公司 2019-02-22 CN disclosed
CN-106892914-B Organic electroluminescent compounds, organic electroluminescence device and its application 南京高光半导体材料有限公司 2019-02-01 CN disclosed
CN-108101922-A Organic electroluminescent compounds, organic electroluminescence device and its application 南京高光半导体材料有限公司 2018-06-01 CN disclosed
CN-106892915-A Organic compound, organic electroluminescence device and its application 南京高光半导体材料有限公司 2017-06-27 CN disclosed
CN-106893581-A Organic electroluminescent compounds, organic electroluminescence device and its application 南京高光半导体材料有限公司 2017-06-27 CN disclosed
EP-0898610-A1 DETERGENT COMPOSITIONS CONTAINING SELECTED MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1999-03-03 EP disclosed
EP-0898606-A1 MID-CHAIN BRANCHED PRIMARY ALKYL ALKOXYLATED SULPHATE SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1999-03-03 EP disclosed
WO-1998023712-A2 POLYOXYALKYLENE SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1998-06-04 WO disclosed
WO-1997039087-A1 MID-CHAIN BRANCHED PRIMARY ALKYL ALKOXYLATED SULPHATE SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 WO disclosed
WO-1997039089-A1 LIQUID CLEANING COMPOSITIONS CONTAINING SELECTED MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 WO disclosed
WO-1997039091-A1 MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 WO disclosed
WO-1997038972-A1 PROCESS FOR MANUFACTURING SULPHATES OF LONGER CHAIN BRANCHED ALKANOLS AND ALKOXYLATED ALKANOLS THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 WO disclosed
WO-1997039090-A1 DETERGENT COMPOSITIONS CONTAINING SELECTED MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099896-A1 Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds GIPR, CHUK, ITPA ACE2 231/4885OPRM1 1842/4885LMNA 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.